Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis
Authors' conclusion
The use of semaglutide reduced 76% in hospitalization due to HF, 17% deaths due to cardiovascular causes, 21% deaths due to any cause, 24% non-fatal myocardial infarction, 24% coronary revascularization and 35% stroke (in patients with diabetes). The use of semaglutide was associated with a higher relative risk and frequency of most adverse effects evaluated.
Study context
- Population
- Individuals with overweight or obesity38 articles
- Comparison
- Semaglutide vs comparator
- Outcome
- CV outcomes (RR)
Methodological detailsDatabases: Pubmed, Lilacs, Scielo, Scopus, Web of Science, Cochrane Library
- Databases: Pubmed, Lilacs, Scielo, Scopus, Web of Science, Cochrane Library
Pooled result
As reported in the abstract
- RR, hospitalization due to heart failure (HF) (n = 2; 1045 participants; I² = 0.18)
- 0.24 95% CI 0.12-0.57
- RR, death due to CV causes (n = 3; 24 084 participants; I² = 0.21)
- 0.83 95% CI 0.71-0.98
- RR, death from any cause (n = 3; 24 084 participants; I² = 0.07)
- 0.79 95% CI 0.70-0.89
- RR, coronary revascularization (n = 2; 20 951 participants; I² = 0.41)
- 0.76 95% CI 0.69-0.85
- RR, non-fatal MI (n = 3; 24 084 participants; I² = 0.21)
- 0.76 95%CI 0.66-0.88
- Difference between subgroups, favoring subcutaneous route
- p = 0.05
Further pooled results
Stroke, patients with diabetes
- RR of stroke (n = 2; 6480 participants; I² = 0.66)
- 0.65 95% CI 0.44-0.97
Safety
- No difference in constipation frequency between routes of administration or between oral semaglutide doses
- RR of adverse effects significant except for treatment discontinuation with oral semaglutide
- Semaglutide associated with higher relative risk and frequency of most adverse effects evaluated
Original publication
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes (Lond). Published 12 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →